Trial reportBritish journal of haematology2009
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
Trial report in British journal of haematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00117156 (A Phase II Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review.Haematologica · 2013Pooled it
- Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.Blood advances · 2020Trial
- Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.Cancer communications (London, England) · 2019Trial
- Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.Blood · 2017Trial
- Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.Current treatment options in oncology · 2025Review
- Management of Marginal Zone Lymphoma: A Canadian Perspective.Current oncology (Toronto, Ont.) · 2023Review
- Review
- Marginal zone lymphoma: present status and future perspectives.Haematologica · 2022Article
- Article
- Splenic marginal zone lymphoma: a case report and literature review.World journal of surgical oncology · 2020Review
- Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy.Current oncology reports · 2018Review
- Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.Cancer management and research · 2018Review
- IgM monoclonal gammopathy in gastric MALToma.Journal of gastrointestinal cancer · 2014Article
- Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Article
- Splenic marginal zone lymphoma masquerading as cirrhotic hypersplenism for seven years.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2012Article
- Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results.Annals of hematology · 2011Article
- Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma.The Korean journal of hematology · 2011Article
- Rituximab in indolent lymphomas.Seminars in hematology · 2010Review
- Marginal Zone Lymphoma: Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up.Saudi journal of medicine & medical sciencesArticle
Corrections and comments
- Commented on by
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
Abstract
The marginal zone lymphomas (MZLs) are a recently defined group of related diseases that probably arise from a common cell of origin, the marginal zone B cell. Data on therapy for subtypes other than gastric mucosa-associated lymphoid tissue (MALT) lymphoma has been largely limited to retrospective case series. This prospective phase 2 study of fludarabine and rituximab for the treatment of marginal zone lymphomas enrolled 26 patients, 14 with nodal MZL, eight with MALT lymphomas and four with splenic MZL; 81% were receiving initial systemic therapy. Only 58% [95% confidence interval (CI) 37-77%] of patients completed the planned six cycles, due to significant haematological, infectious and allergic toxicity. Four late toxic deaths occurred due to infections [15% (95% CI 4.3-35%)], two related to delayed bone marrow aplasia and two related to myelodysplastic syndrome. Nonetheless, the overall response rate was 85% (95% CI 65-96%), with 54% complete responses. The progression-free survival at 3.1 years of follow-up is 79.5% (95% CI 63-96%). We conclude that, although concurrent fludarabine and rituximab given at this dose and schedule is a highly effective regimen in the treatment of MZLs, the significant haematological and infectious toxicity observed both during and after therapy is prohibitive in this patient population, emphasizing the need to study MZLs as a separate entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.